Tony Philip, MD, FACP, FASCO

Medical Oncologist @northwellhealth focused on #sarcoma #GI. Tweets are my own.

[Aditya Shreenivas MD MS @AdityaSunavs]

Was worth the wait, sharing our real-world analysis of HER2 across solid tumors! 206750 tumors profiled by @carisls for ERBB2 alterations, revealing complex relationships between ERBB2 alterations and HER2 IHC expression. Forever grateful to @Dr_R_Kurzrock for her mentorship.

[The Life Raft Group @Liferaftgroup]

There’s real excitement about the momentum in #GISTresearch w/encouraging evidence pointing to promising treatments & better outcomes as reported at #ASCO26. The PEAK study is one to watch. More ASCO updated to come. #GISTcancer #SarcomaResearch #GISTHope #bezuclastinib

[Jon Trent, MD, PhD @JTrentMDPhD]

Interested in a career in #Sarcoma Medical Oncology? We are hiring @SylvesterCancer !!!! Contact me, @GinaDAmatoMD1 or @EmilyJonczak if interested in hearing more about our outstanding patient care, research and education #TeamSarcoma. #Diversity #Miami #WorkLifeBalance

[The Life Raft Group @Liferaftgroup]

#ASCO26 Highlights from the New Targeted Therapies in Sarcoma session showcased the expanding treatment landscape for #GIST. With multiple new targeted therapies emerging & more options being studied in clinical trials, this is an exciting time for the GIST community.

[Tony Philip, MD, FACP, FASCO @TonyOncDoc]

@NagashreeSeeth1 @ASCO Congrats Naga !

[Tony Philip, MD, FACP, FASCO @TonyOncDoc]

@DevikaDasMD @ASCO @UMMC_Cancer @UMMCnews @UMMCMedicine Congrats Devika , well deserved

[Tony Philip, MD, FACP, FASCO @TonyOncDoc]

@JTrentMDPhD @RobinL_Jones @ASCO @RashmiChughMD @SylvesterCancer @UMiamiHealth @rmmunhoz Congrats Jon and everyone else

[Tony Philip, MD, FACP, FASCO @TonyOncDoc]

@ipreeshagul @GlopesMd @BernabeCarolina @COlazagasti @Florez_Lab @NarjustFlorezMD @ASCO @MountSinaiNYC @MSBI_IM @MontefioreNYC @SylvesterCancer @MSKCancerCenter @Latinamd The trail blazing is only beginning for all of you. Can’t wait to see what great things you all will do.

[The Life Raft Group @Liferaftgroup]

Big conferences like #ASCO26 help shape the future of cancer care, and GIST is part of the conversation.
Here are some of the key #GIST research updates we’re watching.

[Jon Trent, MD, PhD @JTrentMDPhD]

@CogentBio Announces @FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with #GIST @SylvesterCancer @Liferaftgroup

https://t.co/4ycFYpA1Mt.

[Tony Philip, MD, FACP, FASCO @TonyOncDoc]

@HannahRAbrams @ShankaranVeena @DrLaraDavis @fredhutch @guptaarjun90 Congrats Dr Abrams ! Eager to know what you learn

[The Life Raft Group @Liferaftgroup]

Get clear insights on #ClinicaTrials, including how they work and what to expect plus a patient’s perspective. https://t.co/NawU0jKxqb #ClinicalTrialsDay #Sarcoma #GISTAwareness

[Tony Philip, MD, FACP, FASCO @TonyOncDoc]

@TumorBoardTues @SunnieSKim @aprilchoi_md @IntegrityCE I’m late to the party but curious if the answer would change if CPS 0 and diffuse type histology

[The Life Raft Group @Liferaftgroup]

These are a few of the ongoing & new GIST clinical trials & programs currently enrolling. If you have questions or need help navigating a #ClinicalTrial, contact: Simran, [email protected] #KQB198 #PEMIGIST #Pemigatinib #StrateGIST3 #ExpandedAccessProgram #Bezuclastinib

[Van Morris, MD @VanMorrisMD]

“Institutions are designed to endure beyond individuals. On the other hand, families are not….Medicine can have extraordinary meaning. But it cannot substitute for being present in your own life. The world may need us as physicians. But the people who love us need us as ourselves.”

Appreciate this profound and thoughtful @JAMA_current editorial by @jenna_taglienti on the importance of MD wellness and priorities- a MUST-READ for all physicians. Wishing you and your family the very best, Dr Taglienti :)

[Tony Philip, MD, FACP, FASCO @TonyOncDoc]

@DevikaDasMD @Ascocancer @UMMCnews @UMMC_Cancer Great to meet you and hearing all your innovative ideas. Looking forward to seeing all the great things you’re going to do at @UMMC_Cancer

[Chordoma Foundation @ChordomaFDN]

We're seeking a Life Sciences Contracts Attorney to help us accelerate chordoma therapy development. If you're an experienced attorney who'd enjoy being embedded within a patient-driven research and drug development organization (or if you know others who may be interested), please apply or spread the word! Details: https://t.co/PXeCLFOsOy

[Patrick Schöffski @schoffski]

Basket trial of the EZH2 inhibitor tazemetostat demonstrated preliminary antitumor activity with responses in rhabdoid tumors, INI1-negative tumors and poorly differentiated chordomas. No responses seen in synovial sarcoma and renal medullary carcinoma. https://t.co/7Mv2foVRGZ

[CTOS @ctosociety]

Gloria Marquina invites you to the CTOS Spring Webinar 2026!
Details and registration: https://t.co/87ILoYAlIC

[Targeted Oncology @TargetedOnc]

Ipsen announced the voluntary withdrawal of tazemetostat from all global markets and for all indications, effective immediately. This decision follows a recommendation from the IDMC based on emerging safety data from the phase 1b/3 SYMPHONY-1 trial. https://t.co/OZ4xCeAsIk